Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Fig. 5

Flow chart. Abbreviations: NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; E, erlotinib; GC, gemcitabine/carboplatin; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; PORT: postoperative radiotherapy; Nad,neoadjuvant; MT, mutant type; WT, wild type

Back to article page